Glenmark Pharmaceuticals Ltd
NSE: GLENMARK BSE: 532296Pharma
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
₹2,349
52W: ₹1370 — ₹2474
PE 44.7 · Book ₹848 · +177% vs bookMarket Cap₹66,297 Cr
Stock P/E44.7Price to Earnings
ROCE9.72%Return on Capital
ROE7.35%Return on Equity
Div. Yield0.11%Face Value ₹1
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
Weaknesses
- −Stock is trading at 2.74 times its book value
- −The company has delivered a poor sales growth of 6.57% over past five years.
- −Company has a low return on equity of 7.72% over last 3 years.
- −Dividend payout has been low at 3.86% of profits over last 3 years
Shareholding Pattern
Promoters46.65%
FIIs20.35%
DIIs19.28%
Public13.7%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.64%▼0.0 | 46.64% | 46.65%▲0.0 | 46.65% |
| FIIs | 20.98% | 23.05%▲2.1 | 23.51%▲0.5 | 23.15%▼0.4 | 20.62%▼2.5 | 20.73%▲0.1 | 19.2%▼1.5 | 20.35%▲1.2 |
| DIIs | 13.93% | 13.21%▼0.7 | 13.85%▲0.6 | 14.6%▲0.8 | 17.64%▲3.0 | 18.61%▲1.0 | 20.09%▲1.5 | 19.28%▼0.8 |
| Public | 18.42% | 17.06%▼1.4 | 15.96%▼1.1 | 15.56%▼0.4 | 15.05%▼0.5 | 13.97%▼1.1 | 14.02%▲0.0 | 13.7%▼0.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,233 | 1,365 | 2,148 | 2,330 | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 | 2,360 |
| Expenses | 1,790 | 1,549 | 1,651 | 1,698 | 1,857 | 1,757 | 1,669 | 1,667 | 1,717 | 1,864 |
| Operating Profit | 443 | -184 | 497 | 631 | 779 | 494 | 341 | 728 | -178 | 496 |
| OPM % | 20% | -14% | 23% | 27% | 30% | 22% | 17% | 30% | -12% | 21% |
| Net Profit | 302 | -20 | 4,614 | 454 | 595 | 414 | 148 | 330 | -739 | 282 |
| EPS ₹ | 10.72 | -0.72 | 163.5 | 16.08 | 21.09 | 14.66 | 5.24 | 11.7 | -26.19 | 10 |
AI Insights
Revenue Trend
TTM revenue at ₹8,303Cr, down 10% YoY. OPM at 17%.
Debt Position
Borrowings at ₹476Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.
Capex Cycle
CWIP at ₹168Cr (8% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 19.28% (+10.18pp change). FIIs: 20.35% (-5.16pp change). Promoters hold 46.65%.
Margin & Efficiency
ROCE declining from 17% (Mar 2014) to 10% (Mar 2025). Working capital days: 55.
Valuation
PE 44.7x with 9.72% ROCE. Price is 177% above book value of ₹848. Dividend yield: 0.11%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 5m - Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Apr - Glenmark receives U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg; U.S. market sales ~$59.2 million.
- Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Regulatory Action/ Inspection 1 Apr - Adjudication order: Rs16.05 crore CGST/SGST demanded plus equal Rs16.05 crore penalty; company to appeal.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse